Home > Publications Database > Digital Outcomes of Upper Limb Ataxia Capture Meaningful Longitudinal Change and Treatment Response > print

001     282538
005     20260105130652.0
024 7 _ |a pmid:40888004
|2 pmid
024 7 _ |a 10.1002/mds.70012
|2 doi
024 7 _ |a 0885-3185
|2 ISSN
024 7 _ |a 1531-8257
|2 ISSN
024 7 _ |a pmc:PMC12661631
|2 pmc
037 _ _ |a DZNE-2025-01301
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Hermle, Dominik
|b 0
245 _ _ |a Digital Outcomes of Upper Limb Ataxia Capture Meaningful Longitudinal Change and Treatment Response
260 _ _ |a New York, NY
|c 2025
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1765544208_25186
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Digital-motor outcomes promise better responsiveness than clinician-reported outcomes in ataxia trials. However, their patient meaningfulness and sensitivity to change remain to be demonstrated, particularly in the upper limb domain.Validation of quantitative motor (Q-Motor) assessment for upper limb ataxia against patient-reported outcomes and regarding sensitivity to both longitudinal and treatment-induced change, the latter in n-of-1 treatment settings.Single-center longitudinal assessment of finger tapping, diadochokinesia, grip-lift, spiral drawing, and target reaching in (1) 36 cross-genotype ataxia patients and 20 controls, validating digital measures for correlations with patient-reported outcome measure (PROM)-ataxia, 2-weeks test-retest reliability, and sensitivity to change within a trial-relevant 1-year follow-up, anchored in Patient Global Impression of Change (PGI-C); and (2) two patients with spinocerebellar ataxia type 27B (SCA27B) on versus off treatment with 4-aminopyridine.Twenty-four digital measures correlated with the PROM-ataxia upper-limb composite (|ρ| = 0.4-0.7) and had excellent test-retest reliability (ICC = 0.91-0.99). Correlations to individual PROM-ataxia items were specific for functional impairment the respective measure was hypothesized to capture. Speed of finger tapping and diadochokinesia, and smoothness of target reaching (spectral arc length of movement in three dimensions [SPARC3D]) captured 1-year progression in ataxia patients (|rprb| = 0.38-0.51), and specifically in patients with worsening PGI-C. Estimated sample sizes to detect longitudinal change were lower for digital than clinical outcomes (SPARC3D: n = 33, Scale for the Assessment and Rating of Ataxia (SARA): n = 79, nine-hole peg-test: n = 214). Speed of diadochokinesia, stability of grip-lift, and variability of target reaching captured treatment responses to 4-aminopyridine in SCA27B, exceeding minimal detectable and minimal important change.Digital upper limb measures capture patient-meaningful 1-year longitudinal and treatment-induced change, and are therefore promising outcomes for upcoming ataxia trials. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: pub.dzne.de
650 _ 7 |a ataxia; clinical outcome assessment; digital motor outcome; patient meaningfulness; sensitivity to change
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Upper Extremity: physiopathology
|2 MeSH
650 _ 2 |a Longitudinal Studies
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Patient Reported Outcome Measures
|2 MeSH
650 _ 2 |a Ataxia: physiopathology
|2 MeSH
650 _ 2 |a Ataxia: drug therapy
|2 MeSH
650 _ 2 |a Reproducibility of Results
|2 MeSH
650 _ 2 |a Treatment Outcome
|2 MeSH
650 _ 2 |a Spinocerebellar Ataxias: physiopathology
|2 MeSH
650 _ 2 |a Spinocerebellar Ataxias: drug therapy
|2 MeSH
650 _ 2 |a Fingers: physiopathology
|2 MeSH
700 1 _ |a Schubert, Robin
|b 1
700 1 _ |a Barallon, Pascal
|b 2
700 1 _ |a Ilg, Winfried
|0 P:(DE-2719)9001643
|b 3
700 1 _ |a Schüle-Freyer, Rebecca
|0 P:(DE-2719)2812018
|b 4
|u dzne
700 1 _ |a Reilmann, Ralf
|0 0000-0002-5904-9517
|b 5
700 1 _ |a Synofzik, Matthis
|0 P:(DE-2719)2811275
|b 6
700 1 _ |a Traschütz, Andreas
|0 P:(DE-2719)9000792
|b 7
|e Last author
773 _ _ |a 10.1002/mds.70012
|g Vol. 40, no. 11, p. 2486 - 2496
|0 PERI:(DE-600)2041249-6
|n 11
|p 2486 - 2496
|t Movement disorders
|v 40
|y 2025
|x 0885-3185
856 4 _ |u https://pub.dzne.de/record/282538/files/DZNE-2025-01301%20SUP.doc
856 4 _ |u https://pub.dzne.de/record/282538/files/DZNE-2025-01301%20SUP.docx
856 4 _ |u https://pub.dzne.de/record/282538/files/DZNE-2025-01301%20SUP.odt
856 4 _ |u https://pub.dzne.de/record/282538/files/DZNE-2025-01301%20SUP.pdf
856 4 _ |u https://pub.dzne.de/record/282538/files/DZNE-2025-01301.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/282538/files/DZNE-2025-01301.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:282538
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 4
|6 P:(DE-2719)2812018
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2811275
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)9000792
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-16
|w ger
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2024-12-16
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOVEMENT DISORD : 2022
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-16
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-16
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-16
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b MOVEMENT DISORD : 2022
|d 2024-12-16
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a UNRESTRICTED
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21